Literature DB >> 22227894

Analysis of the MMP-dependent and independent functions of tissue inhibitor of metalloproteinase-2 on the invasiveness of breast cancer cells.

Logan A Walsh1, Mario A Cepeda, Sashko Damjanovski.   

Abstract

Matrix metalloproteinases (MMPs) are secreted endopeptidases that play an essential role in remodeling the extracellular matrix (ECM). MMPs are primarily active during development, when the majority of ECM remodeling events occurs. In adults, elevated MMP activity has been observed in many pathological conditions such as cancer and osteoarthritis. The proteolytic activity of MMPs is controlled by their natural inhibitors - the tissue inhibitor of metalloproteinases (TIMPs). In addition to blocking MMP-mediated proteolysis, TIMPs have a number of MMP-independent functions including binding to cell surface proteins thereby stimulating signaling cascades. TIMP-2, the most studied member of the family, can both inhibit and activate MMPs directly, as well as inhibit MMP activity indirectly by upregulating expression of RECK, a membrane anchored MMP regulator. While TIMP-2 has been shown to play important roles in breast cancer, we describe how the MMP-independent effects of TIMP-2 can modulate the invasiveness of MCF-7, T47D and MDA-MB-231 breast cancer cells. Using an ALA + TIMP-2 mutant which is devoid of MMP inhibition, but still capable of initiating specific cell signaling cascades, we show that TIMP-2 can differentially affect MMP activity and cellular invasiveness in both an MMP dependent and independent manner. More specifically, MMP activity and invasiveness is increased with the addition of exogenous TIMP-2 in poorly invasive cell lines whereas it is decreased in highly invasive cells lines (MDA-MB-231). Conversely, the addition of ALA + TIMP-2 resulted in decreased invasiveness regardless of cell line.

Entities:  

Year:  2012        PMID: 22227894      PMCID: PMC3368016          DOI: 10.1007/s12079-011-0157-8

Source DB:  PubMed          Journal:  J Cell Commun Signal        ISSN: 1873-9601            Impact factor:   5.782


  33 in total

1.  Assessment of Gelatinases (MMP-2 and MMP-9 by Gelatin Zymography.

Authors:  M Toth; R Fridman
Journal:  Methods Mol Med       Date:  2001

2.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

3.  Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro.

Authors:  M Balduyck; F Zerimech; V Gouyer; R Lemaire; B Hemon; G Grard; C Thiebaut; V Lemaire; E Dacquembronne; T Duhem; A Lebrun; M J Dejonghe; G Huet
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Enhancing effect of platelet-derived microvesicles on the invasive potential of breast cancer cells.

Authors:  Anna Janowska-Wieczorek; Leah A Marquez-Curtis; Marcin Wysoczynski; Mariusz Z Ratajczak
Journal:  Transfusion       Date:  2006-07       Impact factor: 3.157

5.  MMP-2 and MMP-9 synergize in promoting choroidal neovascularization.

Authors:  Vincent Lambert; Ben Wielockx; Carine Munaut; Catherine Galopin; Maud Jost; Takeshi Itoh; Zena Werb; Andrew Baker; Claude Libert; Hans-Willi Krell; Jean-Michel Foidart; Agnès Noël; Jean-Marie Rakic
Journal:  FASEB J       Date:  2003-10-16       Impact factor: 5.191

6.  TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism.

Authors:  Dong-Wan Seo; Hongmei Li; Liliana Guedez; Paul T Wingfield; Tere Diaz; Rita Salloum; Bei-yang Wei; William G Stetler-Stevenson
Journal:  Cell       Date:  2003-07-25       Impact factor: 41.582

7.  Matrix metalloproteinase expression in breast cancer.

Authors:  John E Bartsch; Edgar D Staren; Hubert E Appert
Journal:  J Surg Res       Date:  2003-04       Impact factor: 2.192

Review 8.  Recklessness as a hallmark of aggressive cancer.

Authors:  Makoto Noda; Chiaki Takahashi
Journal:  Cancer Sci       Date:  2007-08-28       Impact factor: 6.716

9.  Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer.

Authors:  H Alakus; G Grass; J K Hennecken; E Bollschweiler; C Schulte; U Drebber; S E Baldus; R Metzger; A H Hölscher; S P Mönig
Journal:  Histol Histopathol       Date:  2008-08       Impact factor: 2.303

10.  IGF-1 increases invasive potential of MCF 7 breast cancer cells and induces activation of latent TGF-β1 resulting in epithelial to mesenchymal transition.

Authors:  Logan A Walsh; Sashko Damjanovski
Journal:  Cell Commun Signal       Date:  2011-05-02       Impact factor: 5.712

View more
  11 in total

1.  Stable expression of α1-antitrypsin Portland in MDA-MB-231 cells increased MT1-MMP and MMP-9 levels, but reduced tumour progression.

Authors:  J A Willson; C A Muir; C L Evered; M A Cepeda; S Damjanovski
Journal:  J Cell Commun Signal       Date:  2017-08-29       Impact factor: 5.782

2.  Anti-elastase, anti-tyrosinase and matrix metalloproteinase-1 inhibitory activity of earthworm extracts as potential new anti-aging agent.

Authors:  Nurhazirah Azmi; Puziah Hashim; Dzulkifly M Hashim; Normala Halimoon; Nik Muhamad Nik Majid
Journal:  Asian Pac J Trop Biomed       Date:  2014-05

3.  TIMP-2 suppresses tumor growth and metastasis in murine model of triple-negative breast cancer.

Authors:  David Peeney; Sandra M Jensen; Nadia P Castro; Sarvesh Kumar; Silvia Noonan; Chenchen Handler; Alex Kuznetsov; Joanna Shih; Andy D Tran; David S Salomon; William G Stetler-Stevenson
Journal:  Carcinogenesis       Date:  2020-05-14       Impact factor: 4.944

4.  Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s).

Authors:  K C Scribner; F Behbod; W W Porter
Journal:  Oncogene       Date:  2012-07-09       Impact factor: 9.867

Review 5.  The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression.

Authors:  Ruth M Escalona; Emily Chan; George Kannourakis; Jock K Findlay; Nuzhat Ahmed
Journal:  Int J Mol Sci       Date:  2018-02-02       Impact factor: 5.923

6.  Diagnostic Power of Cytokine M-CSF, Metalloproteinase 2 (MMP-2) and Tissue Inhibitor-2 (TIMP-2) in Cervical Cancer Patients Based on ROC Analysis.

Authors:  Emilia Lubowicka; Monika Zbucka-Kretowska; Iwona Sidorkiewicz; Monika Zajkowska; Ewa Gacuta; Andrzej Puchnarewicz; Lech Chrostek; Maciej Szmitkowski; Sławomir Ławicki
Journal:  Pathol Oncol Res       Date:  2019-02-28       Impact factor: 3.201

7.  TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells.

Authors:  Dimitra Bourboulia; HuiYing Han; Sandra Jensen-Taubman; Noah Gavil; Biju Isaac; Beiyang Wei; Len Neckers; William G Stetler-Stevenson
Journal:  Oncotarget       Date:  2013-01

8.  Less is more: low expression of MT1-MMP is optimal to promote migration and tumourigenesis of breast cancer cells.

Authors:  Mario A Cepeda; Jacob J H Pelling; Caitlin L Evered; Karla C Williams; Zoey Freedman; Ioana Stan; Jessica A Willson; Hon S Leong; Sashko Damjanovski
Journal:  Mol Cancer       Date:  2016-10-18       Impact factor: 27.401

9.  The matrix protein Fibulin-3 promotes KISS1R induced triple negative breast cancer cell invasion.

Authors:  Michelle M Noonan; Magdalena Dragan; Michael M Mehta; David A Hess; Muriel Brackstone; Alan B Tuck; Navin Viswakarma; Ajay Rana; Andy V Babwah; Frederic E Wondisford; Moshmi Bhattacharya
Journal:  Oncotarget       Date:  2018-07-10

10.  Oral administration of N-acetyl cysteine prevents osteoarthritis development and progression in a rat model.

Authors:  Yosuke Kaneko; Nobuharu Tanigawa; Yuiko Sato; Tami Kobayashi; Satoshi Nakamura; Eri Ito; Tomoya Soma; Kana Miyamoto; Shu Kobayashi; Kengo Harato; Morio Matsumoto; Masaya Nakamura; Yasuo Niki; Takeshi Miyamoto
Journal:  Sci Rep       Date:  2019-12-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.